Navigation Links
PDS Biotechnology Corporation Awarded $1.28M National Cancer Institute Contract
Date:3/2/2010

INDIANAPOLIS, March 2 /PRNewswire/ -- PDS Biotechnology Corporation today announced that the company has been awarded a $1.28M phase 2 SBIR contract by the National Cancer Institute division of the US National Institutes of Health.   The contract provides funding to complete studies required to file an Investigational New Drug Application (IND) with the FDA for the company's lead human papillomavirus (HPV)-cancer product late in 2010.  This curative vaccine, which is based on PDS Biotechnology's Versamune™ platform nanotechnology, has demonstrated potent efficacy in curing HPV infection and HPV-related cancer in preclinical animal and human model studies.  Over 400 million people are infected with the HPV virus and several common cancers are caused by the infection, including cervical, head and neck and anal cancers.  No cures exist for these cancers.  

The award was based on successful completion of a phase 1 SBIR contract demonstrating efficacy of the drug in human model systems, as well as recent GLP toxicology, pharmacokinetic and bio-distribution studies demonstrating an excellent safety profile and efficient uptake of the drug by the immune system.  The new contract will cover over 70% of the costs required to complete the IND-enabling studies.  The remaining 30% of the costs will be covered by non-federal government funds.

PDS Biotechnology's Versamune™ nanotechnology platform facilitates efficient uptake of disease-associated proteins and peptides by cells of the immune system and simultaneously acts a strong immune system modulator without the inflammatory side effects induced by current immune stimulators (also known as adjuvants).  The result is simple, safe and cost effective drugs and vaccines that induce effective eradication of the specific cells infected with, or expressing the particular disease-related protein formulated with Versamune™.  The company's Versamune™-based melanoma product has also demonstrated high efficacy in curing melanoma, which is the most aggressive form of skin cancer, in preclinical animal studies.  

PDS Biotechnology Corporation (www.pdsbiotech.com) is an Indiana-based biotechnology company applying the company's proprietary Versamune™ platform to the development of safe and potent immunotherapies to prevent and to treat cancer and diseases caused by infectious agents.  

This project is funded in part or in whole with Federal Funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services under Contract No. HHSN261200900082C. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

SOURCE PDS Biotechnology Corporation

Back to top

RELATED LINKS
http://www.pdsbiotech.com

'/>"/>

SOURCE PDS Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
2. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
3. Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results
4. Biotechnology Salutes Americas Veterans; Innovations Continue to Offer Improved Treatment and Care of Combat Troops
5. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
6. Eli Lilly and Company Opens Eco-Friendly Biotechnology Center on the West Coast Designed to Speed and Enhance Innovation
7. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
8. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
9. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
10. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
11. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
(Date:6/23/2016)...  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors Luke’s ... June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. ... helping service members that have been wounded in battle and their families. Venture Construction ...
Breaking Medicine News(10 mins):